52 results about "Atopic dermatitis (eczema)" patented technology

The invention discloses a preparation for treating eczema. The preparation is prepared from the following raw materials of liquorice, moutan bark, raw rehmannia root, talc, rhizoma smilacis glabrae, fleece-flower root, peach kernel, fructus forsythiae, honeysuckle, Chinese angelica, poria, zhaici, baikuicai, periostracum cicada, polyporus umbellatus, fructus cnidii, cortex dictamni, divaricate saposhnikovia root, sichuan lovage rhizome, safflower, salviae miltiorrhizae, radix paeoniae alba, astragalus membranaceus, radix sophorae flavescentis, prepared rehmannia, fructus kochiae and burdock, as well as external auxiliary lotion and external auxiliary application. The invention also discloses a method for preparing the preparation for treating eczema. The preparation is prepared from natural traditional Chinese medicinal herbs, simple in components and reasonable in proportion, applies the theory that five drugs penetrating into organs play effect in channels, a comprehensive treatment of internal administration, external lotion and external application is adopted, regulation is performed by internal and external means at the same time, so that the curative effect and the heal rate can be further improved. The preparation has the advantages of high heal rate and extremely good curative effect when being used for treating eczematous dermatitis, rhagadia, atopic dermatitis and other various eczema skin diseases.

An external preparation composition used for preventing or treating symptoms or diseases related to dermatopathy caused by dryness, UV rays and aging such as wrinkles and sags of the skin, pigmentation of the skin, skin roughness and coarse texture and skin diseases such as psoriasis, lichen, ichthyosis, keratosis, Darier's disease, pustulosis, acne, eczema and atopic dermatitis. The external preparation composition comprises at least one of acyl glucosamine derivatives represented by the following Formula (I): wherein R1, R2, R3, R4 and R5 are defined; and X is any one of groups represented by the following Formulas (A) to (C): wherein Y, n and R6 are also defined.

The present invention relates to anti IL13 antibodies that hind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

The invention provides a method and composition for treating dermatoses by topical application of a composition containing an antihistamine, an NSAID and optionally a botanical medicinal compound. The compositions are useful for skin conditions such as inflammatory skin conditions, including eczema, atopic dermatitis, non-allergic dermatitis, psoriasis and rosacea, or any inflammation of the skin.

Disclosed is a non-natural ceramide compound effective for a sphingosine kinase activator, and thus useful for a skin disease treating agent. The sphingosine kinase activator enhances production of sphingosine-1-phosphate to show various physiological activities provided by sphingosine-1-phosphate. The physiological activities include the effects of: controlling multiplication and differentiation of keratinocytes, multiplication of fibroblasts and collagen synthesis, resulting in treatment of wounds, recovery of damaged skin functions in atopic dermatitis and psoriasis; inhibiting wrinkles and skin irritation caused by ultraviolet rays, followed by improvement of wrinkles and inhibition of skin aging; and reducing skin atrophy, which is a typical side effect of local application steroids. Therefore, the sphingosine kinase activator is useful for a skin disease treating agent for treating skin wounds, wrinkles, atopic dermatitis, eczema, psoriasis, or skin atrophy caused by side effects of local application steroids.

The present invention relates to compositions comprising a proanthocyanidin, as well as methods for using such compositions in the treatment of an inflammatory condition of the skin including, but not limited to, atopic dermatitis(eczema), allergic contact dermatitis, seborrheic dermatitis, psoriasis, xerosis and atopia, as well as treatment of an inflammatory condition of mucosae and of an inflammatory condition in the eye. The present invention also relates to compositions comprising a proanthocyanidin, glycyrrhetinic acid and telmesteine, as well as methods for using such compositions in the treatment of an inflammatory condition of the skin including, but not limited to, atopic dermatitis, allergic contact dermatitis, seborrheic dermatitis, radiation dermatitis, psoriasis, xerosis and atopia, as well as treatment of an inflammatory condition of mucosae and of an inflammatory condition in the eye.

The invention provides a micro RNA group related to Th17 differentiation. The micro RNA group comprises micro RNA 4426, micro RNA 3615, micro RNA 106b, micro RNA 590 and micro RNA 573. The micro RNA changes remarkably in the Th17 differentiation process and can be used as Th17 control targets for preparing drugs for treating or preventing Th17-related diseases including lupus erythematosus, dermatomyositis, vasculitis, sicca syndromes, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, scleroderma, multiple sclerosis, malaria, solar dermatitis, eczema, leucoderma, psoriasis, atopic dermatitis, lichen planus, diabetes, coronary heart diseases, hyperlipemia and the like. The micro RNA group is sensitive to hydroxychloroquine intervention and can serve as a sensitive index for judgment of the clinical effect of hydroxychloroquine, and the micro RNA is convenient to test clinically and can be rapidly used for judging the clinical effect of hydroxychloroquine.

The invention discloses a loratadine oral quickly-soluble film and a preparation method thereof. By controlling parameters such as particle size of a loratadine drug, proportion of a film-forming material, content of water of a film product and the like, the product dissolution is improved, the bioavailability can be improved, the preparation can effectively prevent and cure such as allergic rhinitis, chronic idiopathic urticaria, allergic asthma, atopic dermatitis and associated symptoms caused by allergy such as skin diseases (eczema, dermatitis, pruritus cutanea), and the drug effect can be sufficiently realized. The loratadine oral quickly-soluble film does not need water, can be rapidly dissolved in the oral cavity and is convenient to take by patients and particularly suitable for the old people and children patients; moreover, the loratadine oral quickly-soluble film has characteristics of high dispersity, rapidness in absorption, fastness in effect, favorability for improving the bioavailability, and the like.

The invention provides a functional preparation for adjuvant therapy of atopic dermatitis AD and a preparation method thereof. The functional preparation comprising raw material components in parts by weight: 0.2-1 part of sodium hyaluronate, 5-10 parts of emulsifying thickening agent, 5-10 parts of grease and the balance of de-ionized water which enables the total weight to be 100 parts. The functional preparation provided by the invention is the functional preparation containing sodium hyaluronate and is combined with mometasone furoate emulsifiable paste to obviously improve a xerotic eczema symptom, effectively recover a skin barrier function, and reduce the recurrence; the curative effect of the functional preparation combined with mometasone furoate emulsifiable paste is better than that of the single use of the mometasone furoate emulsifiable paste; and the functional preparation can be used for the adjuvant therapy of eczematous dermatitis diseases, has the good curative effect and safety, and reduces the reoccurrence.

This disclosure relates to multifunctional formulations, methods of manufacture and methods of use of natural topical and oral compositions to treat various dermatitis and pruritus conditions in mammals. In particular, this disclosure relates to a multifunctional topical pharmaceutical composition effective to treat dermatitis and associated pruritus comprising at least one natural plant extract TRPV1 antagonist, at least one natural plant extract is a TRPA1 antagonist, and a carrier. Also, in particular, this disclosure also relates to a multifunctional method to treat histamine induced and non-histamine dermatitis and associated pruritus in mammals from one or more of non-atopic and atopic dermatitis (AD), contact dermatitis, allergenic contact dermatitis (ACD), psoriasis, eczema, infestations, urticarial, nociceptive, neuropathic, neurogenic, psychogenic pruritus comprising treating with a composition comprising at least one natural plant extract TRPV1 antagonist, at least one natural plant extract is a TRPA1 antagonist, and a carrier.

This invention relates to a topical pharmaceutical composition comprising a combination of methotrexate, alpha bisabolol and allantoin; a process for producing the same and the use of the composition in the treatment of plaque psoriasis (psoriasis vulgaris), atopic dermatitis and chronic eczema. The composition of this invention can be used alone or in combination with other topical or systemic therapies. The present invention further discloses a process for producing the pharmaceutical composition.

Topical pharmaceutical compositions are described comprising, based on the total weight of the composition: a) 0.01 to 0.2 wt. % of mometasone furoate, b) 5 to 18 wt. % of hexylene glycol, c) 20 to 40 wt. % of water, and d) 25 to 70 wt. % of an oil phase. Said compositions are stable and can be safely and easily applied over large surface areas of the skin in an acceptable way by the general patient population for the treatment or prevention of psoriasis, atopic dermatitis (atopic eczema) and other skin disorders or diseases.

Provided is a novel JAK3 inhibitor useful as a preventive and / or therapeutic agent for organ transplant rejection, graft versus host disease (GvHD), rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, Sjogren's syndrome, Behcet's disease, type I diabetes mellitus, autoimmune thyroiditis, idiopathic thrombocytopenic purpura, ulcerative colitis, Crohn's disease, asthma, allergic conjunctivitis, atopic dermatitis, contact dermatitis, urticaria, eczema, psoriasis, allergic conjunctivitis, uveitis, cancer, leukemia, etc. A pyridine-3-carboxyamide derivative represented by general formula (1) or a salt thereof or a solvate thereof are also provided.

The invention relates to an emollient composition for topical use that comprises a combination of glycerol, Vaseline and liquid paraffin as an active principle, in the form of an oil-in-water or water-in-oil emulsion. The invention also relates to: the use thereof for preparing a drug for treating dry skin conditions associated with certain dermatoses such as atopic dermatitis, ichthyosis conditions and psoriasis; the use thereof for preparing a drug for treating small superficial burns; and the use thereof for preparing a drug for preventing and / or treating and / or reducing the frequency and intensity of eczema attacks observed in patients suffering from atopic dermatitis.

The present invention relates to topical compositions comprising apremilast. It also relates to processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatosis, eczema, rosacea, acne vulgaris, allergies, contact and atopic dermatitis, pruritus, seborrhea, skin cancers, inflammation and other associated skin conditions.

The present invention addresses the problem of providing a coating-forming-type skin composition (coating-type skin protective agent, coating-type skin topical agent, or the like) that does not contain a lower monovalent alcohol such as ethanol and isopropanol, that has excellent quick-drying ability and water resistance, and that is less sticky and provides excellent sensation when being used. The present invention pertains to a coating-forming-type skin composition characterized by containing a specific acrylic polymer, a plasticizing agent, and water, but substantially not containing a lower monovalent alcohol such as ethanol and isopropanol. The composition according to the present invention is extremely useful in the therapy of chronic skin diseases, etc., represented by hand eczema, atopic dermatitis, or the like (i.e., skin diseases with reduced skin barrier function).

The invention provides a pharmaceutical compound. The pharmaceutical compound is a compound shown in the following structural formula or a stereoisomer, a geometrical isomer, a tautomer, a racemate, ahydrate, a solvate, a metabolite and a pharmaceutically acceptable salt or prodrug thereof shown in the specification, wherein R represents 1 to 3 substituents on a benzene ring, and each of the 1 to3 substituents is independently selected from halogen or cyano. The pharmaceutical compound provided by the invention can inhibit JAK kinase, and more particularly can be used as a JAK1 / Tyk2 dual inhibitor and a Tyk2 specific inhibitor. More specifically, the pharmaceutical compound provided by the invention can be used for preventing or treating autoimmune diseases such as rheumatoid arthritis,ankylosing spondylitis, ulcerative colitis, systemic lupus erythematosus, type I diabetes, sicca syndrome, vasculitis, alopecia areata, psoriasis, leucoderma and the like, or other inflammatory skin diseases such as atopic dermatitis, eczema, acne and hidradenitis suppurativa.

The present invention relates to an imidazo[1,2-c]pyrimidinylacetic acid derivative and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The imidazo[1,2-c]pyrimidinylacetic acid derivative of the present invention has excellent CRTH2 (G-protein-coupled chemoattractant receptor, expressed on Th2 cells) antagonistic activity and can be used for the prophylaxis and treatment of diseases associated with CRTH2 activity, in particular for the treatment of allergic diseases, such as asthma, allergic rhinitis, atopic dermatitis, and allergic conjunctivitis; eosinophil-related diseases, such as Churg-Strauss syndrome and sinusitis; basophil-related diseases, such as basophilic leukemia, chronic urticaria and basophilic leukocytosis in human and other mammals; and inflammatory diseases characterized by T lymphocytes and profuse leukocyte infiltrates such as psoriasis, eczema, inflammatory bowel disease, ulcerative colitis, Crohn's disease, COPD (chronic obstructive pulmonary disorder) and arthritis.

The invention discloses an application of fraxinellone in preparation of drugs for treating allergic skin diseases. The allergic skin diseases comprise urticaria, eczema, contact dermatitis, atopic dermatitis, anaphylactoid purpura and drug rash. According to the invention, fraxinellone is used for treating immune globulin E (IgE)-mediated skin diseases for the first time, and fraxinellone can promote Th1 type cells to generate IFN-gamma. 25 mg / kg of fraxinellone is given to mice with passive skin allergy, degranulation of skin tissue mast cells is inhibited, and the inhibition rate reaches 34.01%. 50 mg / kg of fraxinellone is given to mice with passive skin allergy, and the degranulation inhibition rate of skin mast cells reaches 54.34%. 100 mg / kg of fraxinellone is given to mice with passive skin allergy, and the degranulation inhibition rate of skin mast cells reaches 62.5%.

The invention discloses repair emulsion and a preparation method thereof. The repair emulsion comprises the following raw materials in percentage by weight of 0.5-5% of cetearyl glucoside, 0.1-1% of cetearyl alcohol, 0.5-5% of cetearyl olivate, 0.5-5% of sorbitan olivate, 0.5-5% of cyclopentasiloxane, 40-50% of camellia seed oil, 0.5-5% of polydimethylsiloxane, 0.1-1% of pentaerythrityl tetraethylhexanoate, 0.001-0.01% of ceramide 3, 0.1-1% of xanthan gum, 3-10% of glycerine, 3-10% of methylpropanediol, 0.01-0.1% of hydrogenated lecithin, 8-12% of a portulaca oleracea extract, 0.1-1% of polyacrylamide, 0.1-1% of C13-14isoparaffin, 0.1-1% of C9-11 pareth-6, 0.1-1% of hydroxyacetophenone, 0.5-5% of hexanediol and 2-25% of water. Symptoms of atopic dermatitis, eczema, psoriasis and winter dermatitis can be well relieved and improved, and a preparation course is simple and low in cost.

A topical medication including a therapeutically effective amount of an AMPK (adenosine monophosphate-activated protein kinase) agonist for use in the treatment of one or more the human or animal medical conditions. The medical conditions include, but are not limited to: shingles (herpes zoster), post-herpetic neuralgia (PHN), gout, migraine, trigeminal neuralgia, Complex Regional Pain Syndrome (CRPS), diabetic neuropathy, peripheral neuropathy, rheumatoid arthritis, insect-related wheals, urushiol-related rash, psoriasis, herpes simplex, atopic dermatitis (eczema), contact dermatitis, allergic dermatitis, neurotrophic ulcers, first- and second-degree burns (e.g., sunburn and chemical), fibromyalgia, rubeola, and acne. Also disclosed are a method of employing the composition and a wound dressing incorporating a therapeutically effective amount of an AMPK agonist in combination with an antimicrobial agent.

The present invention provides a clobetasol propionate and tretinoin ointment agent. According to the present invention, a phospholipid and a positively charged lipid are mainly adopted to wrap drugs to prepare a lipid complex, wherein the positively charged lipid complex can concurrently wrap two drugs, encapsulation efficiency is high, and leakage is not easily generated; with the lipid complex, drug absorption can be promoted, and drug retention in skin can be increased; the multi-component low co-melting system is adopted to prepare the solid dispersion, such that the composite antioxidant component in the formula is uniformly dispersed in the same system; an oil phase matrix and an emulsifying agent are added so as to further prepare into a cream agent or an ointment agent in one step; and the preparation has characteristics of good emulsifying uniformity and high stability, and can be used for treatment of psoriasis, chronic dermatitis and eczema, skin papule type amyloidopathia, lichen planus, and non-atopic dermatitis.

A carboxylic acid compound represented by formula (I): (meanings of the symbols in the formula are as mentioned in the specification) and a pharmaceutical agent comprising the compound. <>Since the compound represented by formula (I) binds to a DP receptor and shows antagonistic activity for the DP receptor, it is useful for prevention and / or treatment of diseases such as allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like. Carboxylic acid compounds represented by the following general formula (I) (wherein each symbol is as defined in the description) and drugs containing these compounds: (I) Because of binding to DP receptor and antagonizing the same, the compounds represented by the general formula (I) are useful in preventing and / or treating allergic diseases (allergic nephritis, allergic conjunctivitis, atopic dermatitis, bronchial asthma, food allergy, etc.), systemic mast cell disease, systemic mast cell activation failure, anaphylactic shock, respiratory tract contraction, urticaria, eczema, diseases associated with itch (atopic dermatitis, urticaria, etc.), diseases (cataract, retinal detachment, inflammation, infection, sleep disorder, etc.) secondarily caused by behaviors associating itch (scratching, beating.

It is an object of the present invention to provide a film-forming composition for skin (such as a film-type skin protectant or a film-type skin topical agent) that does not contain a lower monohydric alcohol such as ethanol or isopropanol, is excellent in quick-drying properties and water resistance, is less sticky, and is excellent in feeling of use. The present invention relates to a film-forming composition for skin which contains a specific acrylic polymer, a plasticizer and water and is substantially free of a lower monohydric alcohol such as ethanol or isopropanol. The composition of the present invention is extremely useful for treatment of chronic skin diseases (that is, skin diseases in which skin barrier function is deteriorated) represented by hand eczema, atopic dermatitis, and the like.

Provided are various embodiments relating to anti-IL4R antibodies that bind to canine IL4R. In various embodiments, such anti-IL4R antibodies can be used in methods to treat IL4 / IL13-induced conditions, such as atopic dermatitis, allergic dermatitis, pruritus, asthma, psoriasis, scleroderma and eczema, in companion animals, such as canines and felines. Also provided are various embodiments relating to variant IgG Fc polypeptides and variant light chain constant regions of companion animal species for the preparation of antibodies or bispecific antibodies.

To provide a novel JAK3 inhibitor that is useful as a preventive and / or therapeutic agent for rejection and graft versus host disease (GvHD) in organ transplantation, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, Sjögren syndrome, Behcet's disease, type I diabetes mellitus, autoimmune thyroiditis, idiopathic thrombocytopenic purpura, ulcerative colitis, Crohn's disease, asthma, allergic rhinitis, atopic dermatitis, contact dermatitis, urticaria, eczema, psoriasis, allergic conjunctivitis, uveitis, cancer, leukemia and the like. The pyridine-3-carboxyamide derivative represented by the general formula (1): or its salt or a solvate thereof.

The invention relates to a compound preparation for treating skin inflammation and a preparation method thereof. Raw materials of the preparation are coptis roots, nepal dock roots, rose flowers and gallnut. The raw materials are prepared into ointment, gel, tincture, film coating agents or liniments by solvent extraction, impurity removal, and concentration or drying with medical acceptable auxiliary materials. The compound preparation has antibacterial, antiinflammatory, and astringent effects, and can be used for treating skin inflammation comprising acute and chronic eczema, atopic dermatitis, contact dermatitis, and allergic dermatitis. Pharmacodynamic research shows that the compound preparation effectively inhibits NO activity, can inhibit NO release, and can obviously reduce inflammation degree of skin lesions. Through increase of the levels of IL-2, IL-4 and IL-18 reduced by dermatitis and eczema, and reduction of the levels of TNF-alpha and IL-12 increased by dermatitis and eczema, balance of Th1 cells and Th2 cells is achieved, and a treatment role is exerted.

This invention relates to a topical pharmaceutical composition comprising a combination of methotrexate, alpha bisabolol and allantoin; a process for producing the same and the use of the composition in the treatment of plaque psoriasis (psoriasis vulgaris), atopic dermatitis and chronic eczema. The composition of this invention can be used alone or in combination with other topical or systemic therapies. The present invention further discloses a process for producing the pharmaceutical composition.